Mutations in the TP53 (Tumor protein p53) tumour suppressor gene and/or stabilization of the p53 protein were the most frequent molecular aberrations in serous carcinomas, occurring at frequencies in excess of 85%. This evidence concerns the gene TP53 and serous adenocarcinoma.